Table II.

Association between PHD3 and HIF2α expression and clinicopathological parameters in HCC (detected by immunohistochemistry).

	PHD3					HIF2α
Variable	+	−	+%	χ2	P-value	+	−	+%	χ2	P-value
Age, years
<50	44	20	68.8	0.525	0.469	26	38	40.6	0.002	0.960
≥50	12	8	60.0			8	12	40.0
Sex
Male	48	22	68.6	0.686	0.408	28	42	40.0	0.040	0.842
Female	8	6	57.1			6	8	42.9
Tumor size, cm
≤5	42	10	80.8	12.216	<0.001b	26	26	50.0	2.844	0.092
>5	14	18	43.8			8	24	25.0
AFP
<400	32	20	61.5	1.615	0.204	24	28	46.2	1.826	0.177
≥400	24	8	75.0			10	22	31.2
TNM stage
I–II	38	22	63.3	1.050	0.306	26	34	43.3	0.712	0.399
III–IV	18	6	75.0			8	16	33.3
Edmonson
I–II	38	8	82.6	11.629	0.001a	22	24	47.8	2.280	0.131
III–IV	18	20	47.4			12	26	31.6
Portal vein tumor thrombus
No	46	26	63.9	1.750	0.186	30	42	41.7	0.296	0.586
Yes	10	2	83.3			4	8	33.3

+, Positive; -, Negative; +%, Positive rate

^aP<0.01

^bP<0.001. PHD3, prolyl hydroxylase 3; HIF2α, hypoxia-inducible factor 2α; HCC, hepatocellular carcinoma; TNM, tumor, node and metastasis; AFP, α-fetoprotein.